Search results for: internal
#33086446 // To Up
Two Fatal Cases of Stress-induced Cardiomyopathy in COVID-19 Patients.
Jae Hyeong Park, Jae Young Moon, Kyung Mok Sohn, Yeon Sook Kim
No related Items
#33086444 // To Up
Myocardial Efficiency: A Reliable Load-independent Parameter of Cardiac Performance?
In Chang Hwang
1930 related Products with: Myocardial Efficiency: A Reliable Load-independent Parameter of Cardiac Performance?1 mg100ug Lyophilized100ul100ug Lyophilized1 mg100ug Lyophilized200 100ug Lyophilized100ug Lyophilized100ug Lyophilized200 1 mg
No related Items
#33086442 // To Up
Clinical Usefulness of Additional Screening for Abdominal Aortic Aneurysm during Transthoracic Echocardiography.
Hyung Bok Park
2385 related Products with: Clinical Usefulness of Additional Screening for Abdominal Aortic Aneurysm during Transthoracic Echocardiography.
No related Items
#33086439 // To Up
Changes in QRS Duration Are Associated with a Therapeutic Response to Sacubitril-valsartan in Heart Failure with Reduced Ejection Fraction.Recent studies have demonstrated that angiotensin receptor neprilysin inhibitors (ARNIs) can reverse the cardiac remodeling effects that occur in heart failure with reduced ejection fraction (HFrEF). These studies have also suggested that ARNIs have favorable effects on ventricular dyssynchrony. We assessed the changes in QRS duration associated with ARNIs in patients with HFrEF.
Bong Joon Kim, Han Su Park, Sung Il Im, Hyun Su Kim, Jung Ho Heo, Tae Joon Cha, Kyoung Im Cho
2609 related Products with: Changes in QRS Duration Are Associated with a Therapeutic Response to Sacubitril-valsartan in Heart Failure with Reduced Ejection Fraction.100 UGcase100100 1 L.
#33086437 2020/10/21 To Up
The influence of long-term administration of SGLT2 inhibitors on blood pressure at the office and at home in patients with type 2 diabetes mellitus and chronic kidney disease.The decrease in blood pressure is thought to play an important role for the renoprotective effects of sodium-glucose cotransporter 2 inhibitors in patients with diabetes mellitus. However, their influence on blood pressure at home has not been well studied. The aim of this study is to clarify how long-term use of sodium-glucose cotransporter 2 inhibitors influence on blood pressure both at the office and at home, and the kidney function. We retrospectively analyzed 102 patients with type 2 diabetes mellitus and chronic kidney disease to whom sodium-glucose cotransporter 2 inhibitors were administered for more than 1 year, and whose blood pressure were monitored both at the office and at home. The blood pressure at the office and at home significantly decreased, and there was a significant positive correlation between both blood pressure values. Controlled, white-coat, and sustained hypertension were observed in 9.8%, 14.7%, and 55.9% of the patients at the beginning of the treatment, which changed to 16.7%, 15.7%, and 48.0% at the time of the survey, however, the ratio of masked hypertension was not changed (19.6%). The cutoff value of mean arterial pressure at home after treatment for the improvement of urine albumin to creatinine ratio was 92.0 mm Hg, with 54.1% of sensitivity and 60.0% of specificity. Sodium-glucose cotransporter 2 inhibitors can be useful for the strict management of blood pressures both at the office and at home. The decrease in blood pressure at home by this treatment might be related to the improvement of diabetic nephropathy.
Takayuki Furuki, Kazuo Kobayashi, Masao Toyoda, Nobuo Hatori, Hiroyuki Sakai, Kazuyoshi Sato, Masaaki Miyakawa, Kouichi Tamura, Akira Kanamori
2691 related Products with: The influence of long-term administration of SGLT2 inhibitors on blood pressure at the office and at home in patients with type 2 diabetes mellitus and chronic kidney disease.100 μg 50 UG200ul200ul100 μg100ug100 100ul100 μg0.1 mg
#33086429 2020/10/21 To Up
The feasibility of polypill for cardiovascular disease prevention in Asian Population.Polypill is a fixed-dose combination of medications with proven benefits for the prevention of cardiovascular disease (CVD). Its role in CVD prevention has been extensively debated since the inception of this concept in 2003. There are two major kinds of polypills in clinical studies. The first is polypill that combines multiple low-dose medications for controlling only one CVD risk factor (such as high blood pressure or high serum cholesterol). These "single-purpose" polypills were mostly developed from original producers and have higher cost. The polypill that combines 3-4 pharmaceutical components, each with potential to reduce one major cardiovascular risk factors is "multi-purpose" or "cardiovascular" polypill. Using data from various clinical trials and from meta-analysis, Wald and Law claimed that this "cardiovascular" polypill when administered to every individual older than 55 years could reduce the incidence of CVD by more than 80%. Several short and intermediate to long-term studies with different cardiovascular polypills in phase II and III trials showed that they could provide better adherence, equivalent, or better risk factor control and quality of life among users as compared to usual care. One recently published randomized controlled clinical trial demonstrated the effectiveness and safety of a four-component polypill for both primary and secondary CVD prevention with acceptable number needed to treat (NNT) to prevent one major cardiovascular event. Considering the slow achievement of CVD prevention in many poor- and middle-income Asian countries and also the need to further improve compliance of antihypertensive and lipid lowering medications in many high-income Asian countries, the concept of "cardiovascular polypill" could be very useful. With further support from ongoing polypill cardiovascular outcome trials, polypill could be the foundation of the population-based strategies for CVD prevention.
Apichard Sukonthasarn, Yook-Chin Chia, Ji-Guang Wang, Jennifer Nailes, Peera Buranakitjaroen, Huynh Van Minh, Narsingh Verma, Satoshi Hoshide, Jinho Shin, Yuda Turana, Jam Chin Tay, Boon Wee Teo, Saulat Siddique, Jorge Sison, Yu-Qing Zhang, Tzung-Dau Wang, Chen-Huan Chen, Kazuomi Kario
1910 related Products with: The feasibility of polypill for cardiovascular disease prevention in Asian Population.500 tests500 MG96 tests95 Tests / Kit96 tests500 tests
#33086427 2020/10/21 To Up
Usefulness of ankle-brachial index calculated using diastolic blood pressure for prediction of mortality in patients with acute myocardial infarction.A low ankle-brachial index (ABI) calculated using systolic blood pressure (SBP) (ABIsbp) is associated with poor cardiovascular outcome in patients with acute myocardial infarction (AMI). ABI is always calculated using SBP clinically. However, there was no study investigating ABI calculated using mean artery pressure (MAP)(ABImap) and diastolic blood pressure (DBP)(ABIdbp) for mortality prediction in AMI patients. Therefore, our study was aimed to investigate the issue. 199 AMI patients were enrolled. Different ABIs were measured by an ABI-form device. The median follow-up to mortality was 64 months. There were 40 cardiovascular and 137 all-cause mortality. The best cutoff values of ABImbp and ABIdbp for mortality prediction were 0.91 and 0.78, respectively. After multivariate analysis, only ABIdbp and ABIdbp < 0.78 could predict cardiovascular mortality (P ≤ .047). However, all of six ABI parameters, including ABIsbp, ABImap, ABIdbp, ABIsbp < 0.90, ABImap < 0.91, and ABIdbp < 0.78, could predict all-cause mortality (P ≤ .048). In a direct comparison of six ABI models for prediction of all-cause mortality, basic model + ABIdbp <0.78 had the highest predictive value (P ≤ .025). In conclusion, only ABIdbp and ABIdbp < 0.78 could predict cardiovascular and all-cause mortality after multivariate analysis in our study. Furthermore, when adding into a basic model, ABIdbp < 0.78 had the highest additively predictive value for all-cause mortality in the six ABI parameters. Hence, calculation of ABI using DBP except SBP might provide an extra benefit in prediction of cardiovascular and all-cause mortality in AMI patients.
Po-Chao Hsu, Wen-Hsien Lee, Cheng-An Chiu, Ying-Chih Chen, Ching-Tang Chang, Wei-Chung Tsai, Chun-Yuan Chu, Tsung-Hsien Lin, Wen-Chol Voon, Wen-Ter Lai, Sheng-Hsiung Sheu, Ho-Ming Su
1023 related Products with: Usefulness of ankle-brachial index calculated using diastolic blood pressure for prediction of mortality in patients with acute myocardial infarction.500 MG1600 100 G250 mg 5 G 1 G 100 UG 1 G
#33086403 2020/10/21 To Up
Presenting Characteristics, Treatment Patterns, and Outcomes among Patients with Venous Thromboembolism during Hospitalization for COVID-19.V
Carmen Fernández-Capitán, Raquel Barba, María Del Carmen Díaz-Pedroche, Patricia Sigüenza, Pablo Demelo-Rodriguez, Carmine Siniscalchi, José María Pedrajas, Ana I Farfán-Sedano, Pavel Eduardo Olivera, Covadonga Gómez-Cuervo, Pilar Llamas, Paula Villares, Olivier Sanchez, Raquel López-Reyes, Judith Catella, Behnood Bikdeli, Ido Weinberg, Alfonso J Tafur, David Jiménez, Manuel Monreal
1074 related Products with: Presenting Characteristics, Treatment Patterns, and Outcomes among Patients with Venous Thromboembolism during Hospitalization for COVID-19.1000 ml 1 mg 1 G100 ml0.1 mg500 2.5 mg100ug1,000 tests100ul
No related Items
Error loading info... Pleas try again later.
#33086362 2020/10/19 To Up
Measurement of Free Plasma Concentrations of Beta-Lactam Antibiotics: An Applicability Study in ICU Patients.To assess the applicability of an ultrafiltration method to determine free plasma concentrations of beta-lactam antibiotics in ICU patients.
Selina Schießer, Florian Hitzenbichler, Martin Georg Kees, Alexander Kratzer, Matthias Lubnow, Bernd Salzberger, Frieder Kees, Christoph Dorn
2102 related Products with: Measurement of Free Plasma Concentrations of Beta-Lactam Antibiotics: An Applicability Study in ICU Patients.100ug100ug100ug16 Arrays/Slide1 mg100ug500 100ug Lyophilized100ug0.1 mg100ug Lyophilized100ug Lyophilized
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 Fax 0032 16 50 90 45
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50 Fax 01 43 25 01 60
52062 Aachen Deutschland
Tel 0241 40 08 90 86 Fax 0241 55 91 05 36
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
Schweiz Züri +41435006251
Česká republika Praha +420246019719
Ireland Dublin +35316526556
Norge Oslo +4721031366
Finland Helsset +358942419041
Sverige Stockholm +46852503438
Ελλάς Αθήνα +302111768494
Magyarország Budapest +3619980547
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
GENTAUR Nederland BV
5521 DG Eersel Nederland
Tel 0208-080893 Fax 0497-517897
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93 Fax 02 36 00 65 94
53 Iskar Str. 1191 Kokalyane, Sofia